Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib

NCT06644495 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
1000
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Qilu Pharmaceutical Co., Ltd.